vTv Therapeutics (VTVT) Reaches $7.11 52-Week High; Spark Therapeutics (ONCE) Had 15 Bullish Analysts

October 12, 2017 - By Maria Brooks

Among 18 analysts covering Spark Therapeutics (NASDAQ:ONCE), 15 have Buy rating, 1 Sell and 2 Hold. Therefore 83% are positive. Spark Therapeutics had 35 analyst reports since August 21, 2015 according to SRatingsIntel. As per Friday, August 25, the company rating was maintained by Cantor Fitzgerald. TH Capital maintained Spark Therapeutics Inc (NASDAQ:ONCE) on Monday, October 5 with “Buy” rating. The stock of Spark Therapeutics Inc (NASDAQ:ONCE) earned “Buy” rating by Jefferies on Monday, September 4. The company was initiated on Wednesday, September 6 by Barclays Capital. On Thursday, July 6 the stock rating was maintained by BMO Capital Markets with “Buy”. The rating was maintained by Jefferies with “Buy” on Wednesday, August 2. Cowen & Co maintained the shares of ONCE in report on Wednesday, August 2 with “Buy” rating. The firm has “Sell” rating given on Wednesday, September 2 by Zacks. The firm earned “Buy” rating on Wednesday, August 2 by Stifel Nicolaus. The rating was maintained by Cantor Fitzgerald on Tuesday, October 10 with “Buy”. See Spark Therapeutics Inc (NASDAQ:ONCE) latest ratings:

10/10/2017 Broker: BMO Capital Markets Rating: Buy New Target: $89.0 Maintain
10/10/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $94.0 Maintain
06/10/2017 Broker: Goldman Sachs Rating: Buy New Target: $87.0
14/09/2017 Broker: RBC Capital Markets Rating: Buy New Target: $100.0 Initiate
06/09/2017 Broker: Barclays Capital Rating: Buy New Target: $104.0 Initiate
04/09/2017 Broker: Jefferies Rating: Buy New Target: $95.0 Maintain
25/08/2017 Broker: Cantor Fitzgerald Rating: Buy Maintain
17/08/2017 Broker: Evercore Rating: In-Line New Target: $83 Initiates Coverage On
02/08/2017 Broker: Stifel Nicolaus Rating: Buy New Target: $92.0000 Maintain
02/08/2017 Broker: Jefferies Rating: Buy New Target: $95.0000 Maintain

The stock of vTv Therapeutics Inc (NASDAQ:VTVT) hit a new 52-week high and has $7.32 target or 3.00% above today’s $7.11 share price. The 8 months bullish chart indicates low risk for the $233.27 million company. The 1-year high was reported on Oct, 12 by Barchart.com. If the $7.32 price target is reached, the company will be worth $7.00M more. About 15,520 shares traded. vTv Therapeutics Inc (NASDAQ:VTVT) has declined 0.20% since October 12, 2016 and is downtrending. It has underperformed by 16.90% the S&P500.

Investors sentiment increased to 1.81 in Q2 2017. Its up 0.61, from 1.2 in 2017Q1. It is positive, as 7 investors sold Spark Therapeutics Inc shares while 29 reduced holdings. 19 funds opened positions while 46 raised stakes. 27.22 million shares or 1.96% more from 26.70 million shares in 2017Q1 were reported. The New York-based Millennium Ltd has invested 0.06% in Spark Therapeutics Inc (NASDAQ:ONCE). Citigroup Inc has 0% invested in Spark Therapeutics Inc (NASDAQ:ONCE) for 73,951 shares. Tocqueville Asset Mngmt Lp has invested 0.03% in Spark Therapeutics Inc (NASDAQ:ONCE). Envestnet Asset Management holds 0% of its portfolio in Spark Therapeutics Inc (NASDAQ:ONCE) for 128 shares. Victory Capital Mgmt reported 417,410 shares. 5,387 are owned by Prelude Capital Mngmt Llc. Amg Natl Trust State Bank has invested 0.02% in Spark Therapeutics Inc (NASDAQ:ONCE). Alliancebernstein Limited Partnership holds 0% of its portfolio in Spark Therapeutics Inc (NASDAQ:ONCE) for 60,500 shares. Susquehanna Gru Ltd Liability Partnership has 0% invested in Spark Therapeutics Inc (NASDAQ:ONCE) for 29,371 shares. Sg Americas Securities Limited Com reported 0% of its portfolio in Spark Therapeutics Inc (NASDAQ:ONCE). Td Asset Management reported 0.01% of its portfolio in Spark Therapeutics Inc (NASDAQ:ONCE). Point72 Asia (Hong Kong) Ltd holds 9 shares. Pointstate Capital L P holds 0.03% or 43,000 shares. Cadian Capital L P invested in 0.09% or 30,000 shares. Pacad Inv Limited stated it has 3,500 shares.

Spark Therapeutics, Inc. is a gene therapy company. The company has market cap of $3.09 billion. The Firm focuses on treating orphan diseases. It currently has negative earnings. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases.

It is down 13.53% since October 12, 2016 and is uptrending. It has underperformed by 3.17% the S&P500.

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company. The company has market cap of $233.27 million. The Firm is engaged in the discovery and development of orally administered small molecule drug candidates. It currently has negative earnings. The Company’s drug candidate for the treatment of Alzheimer’s disease is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial.

Among 3 analysts covering vTv Therapeutics Inc (NASDAQ:VTVT), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. vTv Therapeutics Inc has $24 highest and $15 lowest target. $18.67’s average target is 162.59% above currents $7.11 stock price. vTv Therapeutics Inc had 3 analyst reports since August 24, 2015 according to SRatingsIntel. The rating was initiated by Stifel Nicolaus on Monday, August 24 with “Buy”. Canaccord Genuity initiated vTv Therapeutics Inc (NASDAQ:VTVT) rating on Friday, September 4. Canaccord Genuity has “Buy” rating and $15 target. The rating was initiated by Piper Jaffray on Monday, August 24 with “Overweight”.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Twitter Auto Publish Powered By : XYZScripts.com